How important is early diagnosis of subclinical atherosclerosis in primary Sjogren's syndrome patients?

Basit Öğe Kaydı
dc.contributor.authorKurt, Tolga
dc.contributor.authorGokmen, Ferhat
dc.contributor.authorAdam, Gurhan
dc.contributor.authorOzcan, Sedat
dc.contributor.authorOzbudak, Ersan
dc.contributor.authorAkbal, Ayla
dc.contributor.authorTemiz, Ahmet
dc.date.accessioned2025-01-27T19:05:51Z
dc.date.available2025-01-27T19:05:51Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Cardiovascular (CV) disease is observed with increasing frequency in patients with systemic vasculitis. The use of carotid intima media thickness (CIMT) and ankle brachial pressure index (ABPI) may help to identify high-risk primary Sjogren's syndrome (PSS) patients. The objective of this study is to determine abnormal ABPI and CIMT values in the patient group with PSS and compare them clinically and serologically with a control group. Materials and methods: Our study comprised a total of 124 patients who were diagnosed with PSS according to the American-European Consensus Group Sjogren's syndrome classification criteria and monitored for more than 3 years, and a control group. CIMT and ABPI measurements were completed by specialists. The patients were also evaluated serologically. Results: All of the PSS patients had xerophthalmia findings, the second most common symptom was xerostomia. The mean disease duration was 80.4±25.6 months. Nine PSS patients (41%) had ABPI less than 0.9. In the control group 11 (11%) patients had ABPI less than 0.9. When the two groups were compared, the difference was found to be significant (p<0.05). PSS patients also exhibited a statistically significant increase in mean CIMT values (mm; p<0.05). When the PSS patients with ABPI less than 0.9 were compared with other PSS patients and the control group, there was no significant difference in terms of anti-Sjogren's syndrome related antigen A (anti-SSA) and anti-Sjogren's syndrome related antigen B (anti-SSB), C-reactive protein (CRP), rheumatoid factor (RF) or Anti-Cyclic Citrullinated Peptide (anti-CCP) positivity (p>0.05). Conclusion: Similar to patients with systemic vasculitis, PSS patients should be assessed for subclinical peripheral arterial diseases in the early stage and monitored closely with ABPI and CIMT measurements. The atherosclerotic process observed in PSS patients may be due not only to the inflammatory effect, but to many multifactorial issues such as immunological and genetic effects.
dc.identifier.endpage749
dc.identifier.issn0393-6384
dc.identifier.issue3
dc.identifier.scopus2-s2.0-84944274378
dc.identifier.scopusqualityN/A
dc.identifier.startpage741
dc.identifier.urihttps://hdl.handle.net/20.500.12428/14012
dc.identifier.volume31
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherActa Medica Mediterranea
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250125
dc.subjectAnkle brachial index; Carotid intima media thickness; Primary Sjogren's syndrome
dc.titleHow important is early diagnosis of subclinical atherosclerosis in primary Sjogren's syndrome patients?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu